Want to see EXOZ full AI Analyst Report?
EXOZ Stock Chart & Stats
$4.40
$0.20(4.55%)
At close: 4:00 PM EDT
$4.40
$0.20(4.55%)
Day’s Range― - ―
52-Week Range$4.35 - $18.40
Previous Close$4.6
Volume4.70K
Average Volume (3M)2.40K
Market Cap
$42.69M
Enterprise Value$53.39M
Total Cash (Recent Filing)$1.44M
Total Debt (Recent Filing)$1.16M
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.15
Shares Outstanding9,281,359
10 Day Avg. Volume1,191
30 Day Avg. Volume2,398
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)26.89
Price to Sales (P/S)0.00
P/FCF Ratio-13.69
Enterprise Value/Market Cap1.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-14.65K
Enterprise Value/Ebitda-5.42
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Non-dilutive NIH FundingThe $2.03M NIH Phase IIB award provides two-year non-dilutive funding targeted at cannabinoid enzyme development and preclinical assays. This reduces near-term financing pressure, directly funds R&D milestones, and strengthens the company’s ability to advance candidates and attract partners without immediate equity dilution.
Diversified Pipeline & PlatformHaving both the NCT program and a second biosolution focused on scalable, cell-free cannabinoid production diversifies technical risk and commercial pathways. The AI-enabled exozyme platform and scalable manufacturing capabilities create a structural competitive edge for producing rare, high-purity molecules attractive to drug developers and partners.
Proven Capital-market AccessRecent successful registered and underwritten offerings show the company can tap public capital and use its shelf registration to raise funds. Reliable market access is a durable operational strength for an early-stage biotech, enabling continuity of R&D and milestone execution while formal financing channels remain available.
Bears Say
Pre-revenue, Widening LossesThe company remains pre-commercial with escalating operating losses and persistently negative operating and free cash flow. Without near-term revenue, continuing burn increases reliance on external financing and elevates execution risk: sustained losses can delay development timelines and pressure resources over the next several quarters.
Shrinking Equity BaseA materially reduced equity cushion reflects cumulative losses and financing effects, weakening the balance sheet buffer against future setbacks. With a much smaller equity base, the company has less financial flexibility and future capital raises become more dilutive or costly, amplifying shareholder dilution risk if losses persist.
Warrant Structures & Dilution OverhangFrequent equity raises with complex warrants and reset clauses create significant potential dilution and a structural overhang. Reset and deep-discount exercise provisions can materially increase outstanding share counts if triggered, complicating capitalization, deterring long-term investors, and pressuring per-share economics over multiple funding cycles.
eXoZymes News
EXOZ FAQ
What was eXoZymes’s price range in the past 12 months?
eXoZymes lowest stock price was $4.35 and its highest was $18.40 in the past 12 months.
What is eXoZymes’s market cap?
eXoZymes’s market cap is $42.69M.
When is eXoZymes’s upcoming earnings report date?
eXoZymes’s upcoming earnings report date is Aug 18, 2026 which is in 17 days.
How were eXoZymes’s earnings last quarter?
Currently, no data Available
Is eXoZymes overvalued?
According to Wall Street analysts eXoZymes’s price is currently Overvalued.
Does eXoZymes pay dividends?
eXoZymes does not currently pay dividends.
What is eXoZymes’s EPS estimate?
eXoZymes’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does eXoZymes have?
eXoZymes has 9,281,359 shares outstanding.
What happened to eXoZymes’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of eXoZymes?
Currently, no hedge funds are holding shares in EXOZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
eXoZymes Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-65.13%
Trailing 12-Months
Company Description
eXoZymes
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.
EXOZ Earnings Call
Q4 2026
0:00 / 0:00
Technical Analysis
Ownership Overview
15.59% Insiders
0.45% Mutual Funds
― Other Institutional Investors
83.27% Public Companies and
Individual Investors